相关实验视频
Updated: Jul 18, 2025

07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
141
了解和治疗异常性肺纤维化症的进展:最近的见解和新兴疗法
Hehua Guo1, Jiazheng Sun1, Siyu Zhang1
1Department of Respiratory Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in pharmacology
|August 23, 2023
概括
异形性肺纤维化 (IPF) 是一种渐进的肺部疾病. 目前的治疗方法减缓衰退,但不能治愈,需要对新疗法的研究.
科学领域:
- 肺部病理学 肺部病理学
- 纤维性疾病 纤维性疾病
- 翻译医学是一种翻译医学.
背景情况:
- 异形性肺纤维化 (IPF) 是一种慢性,渐进的间歇性肺病,原因不明.
- 纤维细胞转变为肌纤维细胞和细胞外矩阵积累是IPF进展的关键.
- 目前的抗纤维性药物 (皮尔芬尼,宁泰达尼布) 缓慢疾病,但没有治愈作用.
研究的目的:
- 审查IPF诊断,病因学和病理学方面的最新进展.
- 讨论IPF新兴的治疗策略.
- 提供IPF当前研究环境的全面概述.
主要方法:
- 对IPF最近研究的文献综述.
- 诊断标准和病因因素的分析.
- 评估病理机制和治疗目标.
主要成果:
- 皮尔费尼和宁泰达尼布在减缓肺功能衰退和减少恶化方面表现出有效性.
- 肺移植仍然是IPF的唯一潜在治疗方法.
- 许多新的治疗策略正在研究中.
结论:
- IPF仍然是一个重要的临床挑战,需要进一步的研究.
- 了解IPF机制的进步正在为新疗法铺平道路.
- 该审查强调了对超越当前选择的创新治疗方法的关键需求.
更多相关视频
相关概念视频
COPD: Pathogenesis and Clinical Features
341
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
341
Pulmonary Hypertension: Classification and Pathogenesis
222
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
222
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194

